Skip to main content
. 2014 Mar 10;9(3):e91587. doi: 10.1371/journal.pone.0091587

Figure 6. Effect of CDK inhibitor deficiency on cardiac allograft rejection.

Figure 6

Kaplan-Meier survival curves for B6 (red lines), p27kip1−/− (blue lines) and p18ink4c−/− (green lines) B6 recipients of BALB/c heterotopic cardiac allograft treated with control Ig (A, 200 µg i.p. on days 0, 2, and 4), CTLA-4Ig (B, 200 µg i.p. on days 0, 2, and 4) or anti-CD154 mAb (C, MR1, 200 µg i.v. on day 0). Mean survival times (MST) for the control Ig groups are: B6 MST = 7, n = 3; p27kip1−/− MST = 7, n = 3, p18ink4c−/− MST = 7, n = 3. MST for the CTLA-4Ig groups are: B6 MST = 18 days, n = 9; p27kip1−/− MST = 17 days, n = 5; p18ink4c−/− MST = 60 days, n = 4, p<0.05. MST for the anti-CD154 groups are: B6 MST = 55 days, n = 5, p27kip1−/− MST = 57 days, n = 5, p18ink4c−/− MST>135 days, n = 5, p<0.05.